Get the Stockscreener App
12.52
4.29%
0.515
Jade Biosciences Inc stock is traded at $12.52, with a volume of 297.04K.
It is up +4.29% in the last 24 hours and up +39.06% over the past month.
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
See More
Previous Close:
$12.00
Open:
$11.95
24h Volume:
297.04K
Relative Volume:
1.77
Market Cap:
$575.74M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.28%
1M Performance:
+39.06%
6M Performance:
+73.58%
1Y Performance:
+0.00%
1-Day Range:
$11.56
$13.08
1-Week Range:
$11.32
$13.21
52-Week Range:
$6.565
$13.57
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
(781) 312-3013
Address
221 CRESCENT ST., WALTHAM
Compare JBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
12.52 | 552.05M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Initiated | BTIG Research | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Latest News
Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect? - Zacks Investment Research
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives $19.75 Average Price Target from Brokerages - Defense World
Is Jade Biosciences Inc. stock resilient to inflationWeekly Trade Analysis & Daily Growth Stock Investment Tips - BỘ NỘI VỤ
Jade Biosciences Inc (JBIO) looking to reclaim success with recent performance - Setenews
Clear Street Initiates Coverage of Jade Biosciences (JBIO) with Buy Recommendation - Nasdaq
Clear Street initiates Jade Biosciences stock with Buy rating on IgAN therapy - Investing.com Canada
How Jade Biosciences Inc. stock performs after earnings2025 Top Gainers & High Win Rate Trade Tips - newser.com
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock - MSN
Guggenheim Maintains Jade Biosciences (JBIO) Buy Recommendation - MSN
Detecting support and resistance levels for Jade Biosciences Inc.Short Setup & Weekly High Conviction Trade Ideas - newser.com
How Jade Biosciences Inc. stock performs during Fed tightening cyclesJuly 2025 Outlook & Short-Term High Return Strategies - newser.com
Is Jade Biosciences Inc. forming a reversal patternJuly 2025 Analyst Calls & Proven Capital Preservation Methods - newser.com
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know - Zacks Investment Research
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga
Does Jade Biosciences Inc. fit your quant trading modelWeekly Gains Report & Reliable Volume Spike Trade Alerts - newser.com
Jade Biosciences Advances Autoimmune Therapies - MSN
Multi asset correlation models including Jade Biosciences Inc.Quarterly Trade Review & Reliable Entry Point Alerts - newser.com
Jade Biosciences files for offering of up to 16.1 million shares of common stock by the selling stockholdersSEC filing - MarketScreener
Wedbush Adjusts Price Target on Jade Biosciences to $19 From $18, Maintains Outperform Rating - MarketScreener
JBIO: Strong pipeline progress and financing extend cash runway into 2028 despite higher net loss - TradingView
Jade Biosciences Reports Q3 2025 Financial Results - TipRanks
Jade Biosciences, Inc. SEC 10-Q Report - TradingView
How Jade Biosciences Inc. stock reacts to inflationary pressuresSell Signal & Daily Volume Surge Trade Alerts - newser.com
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Will Jade Biosciences Inc. see short term momentumWeekly Trend Summary & Safe Capital Growth Plans - newser.com
Jade Biosciences (JBIO) Price Target Increased by 13.43% to 19.38 - MSN
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 - The Manila Times
Jade Biosciences, Inc. Presents New Data Demonstrating A Favorable Preclinical Safety Profile of Jade101 and a Translational Analysis of April Mediated Biomarker Responses At the American Society of Nephrology Kidney Week 2025 - MarketScreener
Jade Biosciences (NASDAQ: JBIO) shows 55–68% IgA reductions in NHPs; JADE101 safety data - Stock Titan
Jade Biosciences Presents New Data Demonstrating a - GlobeNewswire
Jade Biosciences Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Jade Biosciences Inc Stock (JBIO) Financials Data
There is no financial data for Jade Biosciences Inc (JBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):